Comparison of concordant and discordant encounters for patients with RA, axSpA, and PsA according to patient characteristics. Numbers based on first encounters. Values are n (%) or median (IQR) unless otherwise specified.
| Characteristics | RA | AxSpA | PsA | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PtGA > PGA, Discordant | PtGA = PGA, Concordant | p | All Encounters | PtGA > PGA, Discordant | PtGA = PGA, Concordant | p | All Encounters | PtGA > PGA, Discordant | PtGA = PGA, Concordant | p | All Encounters | |
| All encounters | 4065 (49.0) | 4235 (51.0) | < 0.001 | 8300 (100) | 253 (48.3) | 271 (51.7) | < 0.001 | 524 (100) | 824 (56.5) | 634 (43.5) | < 0.001 | 1458 (100) |
| Patient sex | ||||||||||||
| Female | 3119 (50.8) | 3024 (49.2) | < 0.001 | 6143 (100) | 92 (61.7) | 57 (38.3) | < 0.001 | 149 (100) | 500 (60.5) | 326 (39.5) | < 0.001 | 826 (100) |
| Male | 946 (43.9) | 1211 (56.1) | 2157 (100) | 161 (42.9) | 214 (57.1) | 375 (100) | 324 (51.3) | 308 (48.7) | 632 (100) | |||
| Patient age, yrs | 61 (51–69) | 61 (50–69) | 0.285 | 61 (50–69) | 42 (35–53) | 42 (32–51) | 0.257 | 42 (34–52) | 50 (40–58) | 51 (40–59) | 0.439 | 50 (40–58) |
| Disease duration, yrs | 8 (2–16) | 7 (2–14) | 0.001 | 7 (2–15) | 6 (2–15) | 7 (3–15) | 0.076 | 6 (2–15) | 4 (1–10) | 5 (2–11) | 0.047 | 5 (2–10) |
| CRP, mg/l | 6 (3–13) | 5 (2–10) | < 0.001 | 6 (3–11) | 5 (2–12) | 5 (2–9) | 0.572 | 4 (2–10) | 5 (2–9) | 4 (2–9) | 0.174 | 5 (2–9) |
| HAQ, all | ||||||||||||
| patients | 1.1 (0.6– 1.6) | 0.4 (0–1) | < 0.001 | 0.8 (0.3–1.4) | NA | NA | — | NA | 1 (0.5–1.5) | 0.3 (0–0.8) | < 0.001 | 0.6 (0.1–1.1) |
| Female | 1.3 (0.8–1.8) | 0.5 (0.1–1) | < 0.001 | 0.9 (0.4–1.5) | 1.1 (0.8–1.6) | 0.5 (0.1–0.9) | < 0.001 | 0.9 (0.4–1.4) | ||||
| Male | 0.9 (0.4–1.4) | 0.1 (0–0.6) | < 0.001 | 0.5 (0–1) | 0.8 (0.4–1.3) | 0 (0–0.4) | < 0.001 | 0.4 (0–1) | ||||
| Swollen joints | 1 (0–3) | 0 (0–3) | 0.106 | 1 (0–3) | NA | NA | — | NA | 0 (0–2) | 0 (0–1) | 0.012 | 0 (0–1) |
| Tender joints | 2 (0–7) | 1 (0–4) | < 0.001 | 2 (0–5) | NA | NA | — | NA | 2 (0–7) | 0.5 (0–3) | < 0.001 | 1 (0–5) |
| Pain VAS | 51 (32–70) | 17 (7–32) | < 0.001 | 32 (14–57) | 58 (37–72) | 15 (5–30) | < 0.001 | 32 (12–60) | 55 (35–72) | 17 (7–31) | < 0.001 | 36 (18–63) |
| Fatigue VAS | 61 (42–77) | 22 (8–43) | < 0.001 | 42 (19–67) | 65 (47–77) | 23 (8–41) | < 0.001 | 45 (20–70) | 65 (49–78) | 21 (8–42) | < 0.001 | 50 (22–70) |
| Patient global | ||||||||||||
| VAS | 61 (46–76) | 17 (7–31) | < 0.001 | 39 (17–64) | 63 (47–77) | 16 (5–26) | < 0.001 | 36 (15–65) | 66 (48–80) | 17 (7–28) | < 0.001 | 45 (19–70) |
RA: rheumatoid arthritis; axSpA: axial spondyloarthritis; PsA: psoriatic arthritis; IQR: interquartile range; PtGA: patient’s global assessment; PGA: physician’s global assessment; CRP: C-reactive protein; HAQ: Health Assessment Questionnaire; VAS: visual analog scale (0–100 mm); NA: variable is not applicable for axSpA because not part of the standard measurements in the DANBIO registry.